久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

日本 ,安斯泰來,Astellas,   
安斯泰來制藥集團是一家總部位于日本東京的研發(fā)型制藥企業(yè)，在全球范圍內(nèi)研發(fā)、生產(chǎn)、銷售創(chuàng)新型醫(yī)藥產(chǎn)品。我們的使命是不斷提升企業(yè)價值，致力于通過創(chuàng)新可靠的醫(yī)藥產(chǎn)品為全世界人民的健康做貢獻實現(xiàn)我們的存在意義。

　　安斯泰來已經(jīng)在需要高度專業(yè)技能的器官移植領域和泌尿領域成為全球專業(yè)治療領域領導者。借助獨特的產(chǎn)品線，我們逐步在其他目標領域培養(yǎng)支柱產(chǎn)品。在抗腫瘤領域，我們擁有了先進的抗體藥物研究技術。同時強大的現(xiàn)金流確保我們能夠持續(xù)投資于未來的成長。

　　在2007財務年度 (2007 年 4 月至 2008 年 3 月) 全球凈銷售額達 9,726 億日元（97 億美元）。安斯泰來已經(jīng)成為日本第二大處方藥品公司，全世界排名 20位的制藥企業(yè)。目前全球員工約 14000 人。


為方便廣大患者、醫(yī)師及合作伙伴與安斯泰來制藥（中國）有限公司的積極聯(lián)絡與溝通，及時處理來自各方的咨詢反饋， 安斯泰來中國于即日正式啟用400客戶咨詢專線：4000-8567-99，歡迎使用！

專線服務對象：患者、醫(yī)院、藥房、藥品經(jīng)營公司等。
服務范圍：處理與安斯泰來中國上市產(chǎn)品有關的用藥咨詢、藥品不良反應報告、藥品真?zhèn)伪鎰e咨詢、購藥咨詢、質量投訴等。
工作時間：9:00-17:30（周一至周五），非工作時間可根據(jù)語音提示留言，我們會盡快與您聯(lián)絡！

 Astellas Pharma Inc. (アステラス製薬株式會社, Asuterasu Seiyaku Kabushiki-gaisha?, TYO: 4503) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之內(nèi)製薬株式會社, Yamanouchi Seiyaku Kabushiki-gaisha?) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業(yè)株式會社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha?).

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.

Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.

Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942.

Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinois. Yamanouchi's R&D centre in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.

Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005.

[edit] Products
Some of the key products produced by Astellas include:

Prograf (tacrolimus) - Prevention of post-transplant organ rejection
Protopic (tacrolimus ointment) - Atopic dermatitis (eczema)
Amevive (alefacept) - Plaque psoriasis
VESIcare (solifenacin succinate) - Overactive bladder (OAB)
Flomax (tamsulosin hydrochloride) - Benign prostatic hyperplasia (BPH)
Adenocard (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Adenoscan (adenosine injection) - Pharmacologic stress agent for myocardial perfusion scan
Lexiscan (regadenoson injection) - Pharmacologic stress agent for myocardial perfusion scan
Vaprisol (conivaptan) - Hyponatremia
AmBisome (amphotericin B) - Anti-fungal
Mycamine (micafungin sodium) - Anti-fungal
Vibativ (telavancin) - Antibiotic